BALTIMORE, MD – FASgen, Inc. has been awarded a new $1.4 million SBIR Phase II NIH grant for continued research for obesity. FASgen has for some time had extensive research into the effects of inhibition of the fatty acid biosynthesis pathway on the regulation of appetite and weight loss.

The company has developed numerous families of compounds that act on the well identified targets in the pathway.

“This grant supplements the Company’s extensive product development efforts in the metabolic disease field. The weight loss effects seen to date in preclinical in vivo experiments have applications in various indications, including obesity, diabetes, and fatty liver disease, including specifically non-alcoholic steatohepatitis,” said Susan Medghalchi, Ph.D., FASgen’s principal investigator under the grant.

FASgen is a drug development company founded in 2000 by four Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field.

Online: www.fasgen.com

Southeast Venture Conference, February 29 – March 1, 2012 at the Ritz Carlton in Tysons Corner, VA – Where Smart Money Meets Smart People.
www.seventure.org

© 2009, TechJournal South. All rights reserved.